Media Coverage

Autoimmune diagnostics company Augurex Life Sciences said Friday that it has entered a nonexclusive agreement with Quest Diagnostics under which Quest will validate and offer in the United States a laboratory-developed test based on Augurex's 14-3-3eta biomarker.

Quest Diagnostics and Elevance Health are broadening their partnership into four more states with the goal of making it easier for patients to access in-network laboratory services. Beginning Jan. 1, Quest's service will be available in-network in four additional states: Colorado, Georgia, Nevada and Virginia. This includes routine lab testing, advanced diagnostics and Quest's network of pathologists, according to an announcement.

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus. WHY IT'S IMPORTANT: The spread of bird flu among dairy herds and infections of 27 people this year have alarmed some public health experts.

Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests. Demand for diagnostic checkups has grown in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.

Quest Diagnostics has launched a self-collection option for testing for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium. The test uses Hologic's FDA-cleared Aptima Multi-test swab for patient-collected vaginal specimens and can be used by patients to self-collect specimens in Quest patient service centers or in traditional clinical settings like a doctor's office.